Dicloxacillin Sodium
FDA-approved product (capsule, oral), marketed as Dicloxacillin Sodium, Dycill, Dynapen and 1 more.
- Registered studies
- 17
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Beta-lactamase resistant penicillins
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01CF01
Repurposing investigation
Dicloxacillin Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli26.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae50.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis41.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
17registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dicloxacillin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more47.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents47.8% AI-predicted activityagainst K. pneumoniae1 registered study
- Rezafungin AcetateExisting use: Candidemia, Candidiasis, Candidiasis, Invasive47.6% AI-predicted activityagainst K. pneumoniae5 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection47.3% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- Ergoloid MesylatesExisting use: Cardiovascular disease47.1% AI-predicted activityagainst K. pneumoniae2 registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more47.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma47.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more46.7% AI-predicted activityagainst K. pneumoniae35 registered studies
- Hydrocodone BitartrateExisting use: Cough, Drug dependence, Pain46.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more46.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- AnidulafunginExisting use: Candidemia, Candidiasis, Peritonitis46.1% AI-predicted activityagainst K. pneumoniae43 registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more46.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
NCT00037050 · start 2002-04
Registered record
- Registry ID
- NCT00037050
- Conditions
- Bacterial Infections; Gram-Positive Bacterial Infections; Bacteremia
- Interventions
- Linezolid; Vancomycin; Oxacillin; Dicloxacillin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-04
- Completion
- 2005-07
- Enrolment
- 739
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial Infections; Gram-Positive Bacterial Infections; BacteremiaInterventionLinezolid; Vancomycin; Oxacillin; DicloxacillinPhasePhase 3Registry statusCompletedCefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
NCT07186894 · start 2000-01-01
Registered record
- Registry ID
- NCT07186894
- Conditions
- Bacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
- Interventions
- Antistaphylococcal penicillins; Cefazolin
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Active not recruiting
- Start
- 2000-01-01
- Completion
- 2026-09-01
- Enrolment
- 5,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacteriemia; Methicillin Susceptible Staphylococcus Aureus (MSSA) InfectionInterventionAntistaphylococcal penicillins; CefazolinPhaseNot recordedRegistry statusActive not recruiting